78 related articles for article (PubMed ID: 20355294)
1. Biodistribution analysis of cisplatin in liposomal form in animals with cisplatin-resistant and cisplatin-sensitive carcinoma.
Nosko MM; Pivnyuk VM; Solyanik GI; Kulik GI; Todor IN; Momot VY; Melnikov OR; Ponomareva OV; Chekhun VF
Exp Oncol; 2010 Mar; 32(1):40-3. PubMed ID: 20355294
[TBL] [Abstract][Full Text] [Related]
2. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice.
Júnior AD; Mota LG; Nunan EA; Wainstein AJ; Wainstein AP; Leal AS; Cardoso VN; De Oliveira MC
Life Sci; 2007 Jan; 80(7):659-64. PubMed ID: 17141809
[TBL] [Abstract][Full Text] [Related]
3. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL
Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.
Newman MS; Colbern GT; Working PK; Engbers C; Amantea MA
Cancer Chemother Pharmacol; 1999; 43(1):1-7. PubMed ID: 9923534
[TBL] [Abstract][Full Text] [Related]
5. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and tissue distribution of iv injection of polyphase liposome-encapsulated cisplatin (KM-1) in rats.
Wang S; Mi JB; Li YZ; Chang WB; Ci YX; Zhao MZ; Zhao YK; Zhu LY; Xu G
Acta Pharmacol Sin; 2003 Jun; 24(6):589-92. PubMed ID: 12791187
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.
Staffhorst RW; van der Born K; Erkelens CA; Hamelers IH; Peters GJ; Boven E; de Kroon AI
Anticancer Drugs; 2008 Aug; 19(7):721-7. PubMed ID: 18594214
[TBL] [Abstract][Full Text] [Related]
8. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
[TBL] [Abstract][Full Text] [Related]
9. Alteration in lipid composition of plasma membranes of sensitive and resistant Guerin carcinoma cells due to the action of free and liposomal form of cisplatin.
Naleskina LA; Todor IN; Nosko MM; Lukianova NY; Pivnyuk VM; Chekhun VF
Exp Oncol; 2013 Sep; 35(3):192-7. PubMed ID: 24084457
[TBL] [Abstract][Full Text] [Related]
10. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
[TBL] [Abstract][Full Text] [Related]
11. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma.
Fichtinger-Schepman AM; Vendrik CP; van Dijk-Knijnenburg WC; de Jong WH; van der Minnen AC; Claessen AM; van der Velde-Visser SD; de Groot G; Wubs KL; Steerenberg PA
Cancer Res; 1989 Jun; 49(11):2862-7. PubMed ID: 2720647
[TBL] [Abstract][Full Text] [Related]
12. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
13. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro.
Krieger ML; Eckstein N; Schneider V; Koch M; Royer HD; Jaehde U; Bendas G
Int J Pharm; 2010 Apr; 389(1-2):10-7. PubMed ID: 20060458
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
Deng C; Huang R; Lian L
Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
16. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
18. Ultrastructural changes in tumor cells treated with liposomal forms of anticancer drugs.
Yurchenko OV; Rusetskya NV; Naleskina LA; Chekhun VF
Exp Oncol; 2010 Mar; 32(1):23-8. PubMed ID: 20332761
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution and antitumoral effect of long-circulating and pH-sensitive liposomal cisplatin administered in Ehrlich tumor-bearing mice.
Araújo JG; Mota Ld; Leite EA; Maroni Lde C; Wainstein AJ; Coelho LG; Savassi-Rocha PR; Pereira MT; de Carvalho AT; Cardoso VN; De Oliveira MC
Exp Biol Med (Maywood); 2011 Jul; 236(7):808-15. PubMed ID: 21685237
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
